These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26454800)

  • 1. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
    Kubeček O; Bláha M; Diaz-Garcia D; Filip S
    Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
    Nowak-Markwitz E
    Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
    Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
    Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
    Duggan ST; Keating GM
    Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
    Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
    Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
    Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
    BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer.
    Wilailak S; Linasmita V
    Oncology; 2004; 67(3-4):183-6. PubMed ID: 15557776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
    Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
    Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
    Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
    Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
    Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
    Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
    Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
    Kubeček O; Martínková J; Chládek J; Bláha M; Maláková J; Hodek M; Špaček J; Filip S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):353-365. PubMed ID: 31728628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.